Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 62 publications
Author Correction: SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial.
Journal: Nature medicine
Published: June 29, 2026
A Phase 2 Trial of RANKL Antibody, Denosumab, in Two Cohorts of Patients with Recurrent/Refractory Osteosarcoma, a Report from the Children's Oncology Group.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 25, 2024
Real-World Response and Survival Outcomes and Treatment Patterns in Patients With Extensive Stage Small-Cell Lung Cancer Receiving Third-Line Treatment.
Journal: Cancer reports (Hoboken, N.J.)
Published: September 16, 2024
A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in Patients with Small Cell Lung Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 24, 2024
Evaluation of the pan-class I phosphoinositide 3-kinase (PI3K) inhibitor copanlisib in the Pediatric Preclinical Testing Consortium in vivo models of osteosarcoma.
Journal: Pediatric blood & cancer
Published: July 01, 2022
Phase 2 study of anti-disialoganglioside antibody, dinutuximab, in combination with GM-CSF in patients with recurrent osteosarcoma: A report from the Children's Oncology Group.
Journal: European journal of cancer (Oxford, England : 1990)
Published: January 26, 2022
Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in Osteosarcoma.
Journal: Molecular cancer therapeutics
Published: October 09, 2021
Trastuzumab Deruxtecan, Antibody-Drug Conjugate Targeting HER2, Is Effective in Pediatric Malignancies: A Report by the Pediatric Preclinical Testing Consortium.
Journal: Molecular cancer therapeutics
Published: September 13, 2021
Prioritization of Novel Agents for Patients with Rhabdomyosarcoma: A Report from the Children's Oncology Group (COG) New Agents for Rhabdomyosarcoma Task Force.
Journal: Journal of clinical medicine
Published: February 27, 2021
Charting a path for prioritization of novel agents for clinical trials in osteosarcoma: A report from the Children's Oncology Group New Agents for Osteosarcoma Task Force.
Journal: Pediatric blood & cancer
Published: January 25, 2021
Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors.
Journal: Cancer medicine
Published: August 19, 2020
Last Updated: 09/26/2026